Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561347 · ClinicalTrials.gov registry record · Phase 2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 4
- Study locations
NCT06561347: Recruiting Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Massachusetts General Hospital.
NCT06561347 is a Phase 2 study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 55 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561347, a Phase 2 study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Primary Outcome
Assessed using 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM11) criteria. All participants will be gauged for very good partial response (VGPR) rate or better.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Rituximab
- DRUG Bendamustine
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Colorado
- Colorado Blood Cancer Institute (CBCI) - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What NCT06561347 shows while recruiting
NCT06561347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT06561347 reports a single indexed study location in Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT06561347 about?
NCT06561347 is a clinical study titled "Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM". The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
What is the current status of trial NCT06561347?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2024-12-20. Estimated completion is 2027-12-01.
What conditions does trial NCT06561347 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT06561347?
The interventions under investigation include: Zanubrutinib (DRUG), Rituximab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT06561347?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561347 being conducted?
This trial has 4 study locations across Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06561347's enrollment target sits among peer trials
55 19th of 34 higher than 16 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI